BDX vs IMDX · P/E 34, rev $21.84B vs rev $271.0K
Becton Dickinson and Company (BDX) versus Insight Molecular Diagnostics Inc. (IMDX) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. IMDX currently screens at market cap $0.
Not investment advice. Open the BDX and IMDX stock pages for the full models.
Not investment advice.